Biomarker Assay Development
LifeSensors has developed a suite of assays for validating ubiquitin pathway drugs in cultured cells and model organisms. Ligase and DUB inhibitors both cause downstream changes in the ubiquitylation state of their protein substrates. The biological consequences of altered ubiquitylation determine the effectiveness of drug treatment. Thus, protein ubiquitylation serves as a biomarker for the activity of DUB- and ligase-based drugs. LifeSensors has pioneered biomarker methodology (UbiTest) that will help you identify in vivo ligase substrates and biomarkers. We have further adapted our TUBE technologies to enable high-throughput assays for cellular substrate ubiquitylation. These biomarker assays enable researchers to distinguish promising lead compounds from off-target compounds. In ligase and DUB drug discovery, connecting the dots is the most important step. Developing structure activity relationships from purified enzymes, to cultured cells, to animal models is key to success in ligase and DUB drug discovery. LifeSensors’ suite of assays and in vivo biomarker technologies can help establish a rank order of potency, the most important step that helps medicinal chemists optimize novel and potent compounds for the clinic.